Needham & Company LLC set a $98.00 target price on CVS Health (NYSE:CVS) in a research note published on Friday morning. The firm currently has a buy rating on the pharmacy operator’s stock.

Other equities analysts have also issued research reports about the company. ValuEngine lowered CVS Health from a buy rating to a hold rating in a research note on Sunday, December 31st. Robert W. Baird restated a hold rating and issued a $77.00 target price on shares of CVS Health in a research note on Friday, October 27th. Mizuho set a $90.00 target price on CVS Health and gave the stock a buy rating in a research note on Tuesday, October 24th. Vetr lowered CVS Health from a hold rating to a sell rating and set a $76.66 target price for the company. in a research note on Tuesday, January 16th. Finally, Loop Capital set a $73.00 target price on CVS Health and gave the stock a hold rating in a research note on Monday, December 4th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $87.77.

Shares of CVS Health (NYSE CVS) opened at $69.87 on Friday. CVS Health has a twelve month low of $66.45 and a twelve month high of $84.00. The company has a current ratio of 1.02, a quick ratio of 0.52 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $70,780.00, a price-to-earnings ratio of 11.84, a PEG ratio of 1.16 and a beta of 0.92.

CVS Health (NYSE:CVS) last issued its earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.88 by $0.04. The company had revenue of $48.39 billion during the quarter, compared to analyst estimates of $47.54 billion. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $1.71 EPS. sell-side analysts expect that CVS Health will post 6.47 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, February 2nd. Shareholders of record on Wednesday, January 24th were given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 2.86%. The ex-dividend date of this dividend was Tuesday, January 23rd. CVS Health’s dividend payout ratio is currently 33.90%.

In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of the stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the sale, the executive vice president now directly owns 15,556 shares of the company’s stock, valued at approximately $1,166,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.61% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the company. Horan Capital Advisors LLC. grew its position in shares of CVS Health by 3.2% during the 2nd quarter. Horan Capital Advisors LLC. now owns 32,115 shares of the pharmacy operator’s stock valued at $2,584,000 after acquiring an additional 1,000 shares during the period. Community Bank N.A. grew its position in shares of CVS Health by 7.3% during the 2nd quarter. Community Bank N.A. now owns 19,976 shares of the pharmacy operator’s stock valued at $1,608,000 after acquiring an additional 1,362 shares during the period. FIL Ltd grew its position in shares of CVS Health by 13.8% during the 2nd quarter. FIL Ltd now owns 514,836 shares of the pharmacy operator’s stock valued at $41,424,000 after acquiring an additional 62,318 shares during the period. Midwest Investment Management LLC grew its position in shares of CVS Health by 6.2% during the 2nd quarter. Midwest Investment Management LLC now owns 21,382 shares of the pharmacy operator’s stock valued at $1,720,000 after acquiring an additional 1,245 shares during the period. Finally, ETRADE Capital Management LLC grew its position in shares of CVS Health by 3.7% during the 2nd quarter. ETRADE Capital Management LLC now owns 55,653 shares of the pharmacy operator’s stock valued at $4,478,000 after acquiring an additional 1,979 shares during the period. Hedge funds and other institutional investors own 80.81% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “CVS Health (CVS) Given a $98.00 Price Target by Needham & Company LLC Analysts” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://theolympiareport.com/2018/02/13/cvs-health-cvs-given-a-98-00-price-target-by-needham-company-llc-analysts.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.